Civil Monetary Penalty (CMP)
Definition
Civil Monetary Penalties (CMPs) in the 340B context are financial penalties authorized under the Affordable Care Act and administered by the HHS Office of Inspector General (OIG). CMPs can be imposed on drug manufacturers who knowingly and intentionally charge covered entities more than the 340B ceiling price.
The CMP authority was established to provide a meaningful enforcement mechanism against manufacturer overcharging. Before CMPs were authorized, covered entities had limited recourse against manufacturers who charged above the ceiling price. The ADR process and CMP authority together create a more robust enforcement framework.
While CMPs are directed at manufacturers rather than covered entities, understanding this provision helps covered entities recognize their rights when they believe they are being overcharged and understand the regulatory framework governing manufacturer pricing obligations.
Frequently Asked Questions
Why Civil Monetary Penalty (CMP) Matters
CMPs represent a significant deterrent against manufacturer overcharging. Covered entities that monitor their pricing accuracy and identify potential overcharges have legal mechanisms available to them, including the ADR process and the CMP framework.
How Virtue 340B Uses It
Virtue 340B monitors pricing accuracy for covered entity clients as part of our audit and monitoring services, helping identify potential overcharges that may warrant further review or ADR proceedings.